Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
17,819
archived clinical trials in
Brain Cancer

Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated:  12/31/1969
Mercy Health Saint Mary's
mi
from
Grand Rapids, MI
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated: 12/31/1969
Mercy Health Saint Mary's
mi
from
Grand Rapids, MI
Click here to add this to my saved trials
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated:  12/31/1969
Spectrum Health Butterworth Hospital
mi
from
Grand Rapids, MI
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated: 12/31/1969
Spectrum Health Butterworth Hospital
mi
from
Grand Rapids, MI
Click here to add this to my saved trials
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated:  12/31/1969
Great Lakes Cancer Management Specialists-Van Elslander Cancer Center
mi
from
Grosse Pointe Woods, MI
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated: 12/31/1969
Great Lakes Cancer Management Specialists-Van Elslander Cancer Center
mi
from
Grosse Pointe Woods, MI
Click here to add this to my saved trials
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated:  12/31/1969
Michigan Breast Specialists-Grosse Pointe Woods
mi
from
Grosse Pointe Woods, MI
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated: 12/31/1969
Michigan Breast Specialists-Grosse Pointe Woods
mi
from
Grosse Pointe Woods, MI
Click here to add this to my saved trials
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated:  12/31/1969
Allegiance Health
mi
from
Jackson, MI
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated: 12/31/1969
Allegiance Health
mi
from
Jackson, MI
Click here to add this to my saved trials
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated:  12/31/1969
Borgess Medical Center
mi
from
Kalamazoo, MI
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated: 12/31/1969
Borgess Medical Center
mi
from
Kalamazoo, MI
Click here to add this to my saved trials
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated:  12/31/1969
Bronson Methodist Hospital
mi
from
Kalamazoo, MI
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated: 12/31/1969
Bronson Methodist Hospital
mi
from
Kalamazoo, MI
Click here to add this to my saved trials
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated:  12/31/1969
West Michigan Cancer Center
mi
from
Kalamazoo, MI
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated: 12/31/1969
West Michigan Cancer Center
mi
from
Kalamazoo, MI
Click here to add this to my saved trials
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated:  12/31/1969
Sparrow Hospital
mi
from
Lansing, MI
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated: 12/31/1969
Sparrow Hospital
mi
from
Lansing, MI
Click here to add this to my saved trials
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated:  12/31/1969
Hope Cancer Clinic
mi
from
Livonia, MI
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated: 12/31/1969
Hope Cancer Clinic
mi
from
Livonia, MI
Click here to add this to my saved trials
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated:  12/31/1969
Saint Mary Mercy Hospital
mi
from
Livonia, MI
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated: 12/31/1969
Saint Mary Mercy Hospital
mi
from
Livonia, MI
Click here to add this to my saved trials
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated:  12/31/1969
Mercy Health Mercy Campus
mi
from
Muskegon, MI
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated: 12/31/1969
Mercy Health Mercy Campus
mi
from
Muskegon, MI
Click here to add this to my saved trials
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated:  12/31/1969
21st Century Oncology-Pontiac
mi
from
Pontiac, MI
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated: 12/31/1969
21st Century Oncology-Pontiac
mi
from
Pontiac, MI
Click here to add this to my saved trials
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated:  12/31/1969
Hope Cancer Center
mi
from
Pontiac, MI
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated: 12/31/1969
Hope Cancer Center
mi
from
Pontiac, MI
Click here to add this to my saved trials
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated:  12/31/1969
Newland Medical Associates-Pontiac
mi
from
Pontiac, MI
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated: 12/31/1969
Newland Medical Associates-Pontiac
mi
from
Pontiac, MI
Click here to add this to my saved trials
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated:  12/31/1969
Saint Joseph Mercy Oakland
mi
from
Pontiac, MI
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated: 12/31/1969
Saint Joseph Mercy Oakland
mi
from
Pontiac, MI
Click here to add this to my saved trials
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated:  12/31/1969
Spectrum Health Reed City Hospital
mi
from
Reed City, MI
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated: 12/31/1969
Spectrum Health Reed City Hospital
mi
from
Reed City, MI
Click here to add this to my saved trials
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated:  12/31/1969
Great Lakes Cancer Management Specialists-Rochester Hills
mi
from
Rochester Hills, MI
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated: 12/31/1969
Great Lakes Cancer Management Specialists-Rochester Hills
mi
from
Rochester Hills, MI
Click here to add this to my saved trials
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated:  12/31/1969
Saint Mary's of Michigan
mi
from
Saginaw, MI
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated: 12/31/1969
Saint Mary's of Michigan
mi
from
Saginaw, MI
Click here to add this to my saved trials
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated:  12/31/1969
Oncology Hematology Associates of Saginaw Valley PC
mi
from
Saginaw, MI
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated: 12/31/1969
Oncology Hematology Associates of Saginaw Valley PC
mi
from
Saginaw, MI
Click here to add this to my saved trials
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated:  12/31/1969
Marie Yeager Cancer Center
mi
from
Saint Joseph, MI
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated: 12/31/1969
Marie Yeager Cancer Center
mi
from
Saint Joseph, MI
Click here to add this to my saved trials
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated:  12/31/1969
Bhadresh Nayak MD PC-Sterling Heights
mi
from
Sterling Heights, MI
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated: 12/31/1969
Bhadresh Nayak MD PC-Sterling Heights
mi
from
Sterling Heights, MI
Click here to add this to my saved trials
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated:  12/31/1969
Munson Medical Center
mi
from
Traverse City, MI
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated: 12/31/1969
Munson Medical Center
mi
from
Traverse City, MI
Click here to add this to my saved trials
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated:  12/31/1969
Great Lakes Cancer Management Specialists-Macomb Professional Building
mi
from
Warren, MI
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated: 12/31/1969
Great Lakes Cancer Management Specialists-Macomb Professional Building
mi
from
Warren, MI
Click here to add this to my saved trials
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated:  12/31/1969
Macomb Hematology Oncology PC
mi
from
Warren, MI
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated: 12/31/1969
Macomb Hematology Oncology PC
mi
from
Warren, MI
Click here to add this to my saved trials
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated:  12/31/1969
Michigan Breast Specialists-Warren
mi
from
Warren, MI
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated: 12/31/1969
Michigan Breast Specialists-Warren
mi
from
Warren, MI
Click here to add this to my saved trials
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated:  12/31/1969
Saint John Macomb-Oakland Hospital
mi
from
Warren, MI
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated: 12/31/1969
Saint John Macomb-Oakland Hospital
mi
from
Warren, MI
Click here to add this to my saved trials
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated:  12/31/1969
Saint Mary's Oncology/Hematology Associates of West Branch
mi
from
West Branch, MI
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated: 12/31/1969
Saint Mary's Oncology/Hematology Associates of West Branch
mi
from
West Branch, MI
Click here to add this to my saved trials
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated:  12/31/1969
Metro Health Hospital
mi
from
Wyoming, MI
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated: 12/31/1969
Metro Health Hospital
mi
from
Wyoming, MI
Click here to add this to my saved trials
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated:  12/31/1969
Huron Gastroenterology PC
mi
from
Ypsilanti, MI
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated: 12/31/1969
Huron Gastroenterology PC
mi
from
Ypsilanti, MI
Click here to add this to my saved trials
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated:  12/31/1969
IHA Hematology Oncology Consultants-Ann Arbor
mi
from
Ypsilanti, MI
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated: 12/31/1969
IHA Hematology Oncology Consultants-Ann Arbor
mi
from
Ypsilanti, MI
Click here to add this to my saved trials
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated:  12/31/1969
Fairview Ridges Hospital
mi
from
Burnsville, MN
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated: 12/31/1969
Fairview Ridges Hospital
mi
from
Burnsville, MN
Click here to add this to my saved trials
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated:  12/31/1969
Mercy Hospital
mi
from
Coon Rapids, MN
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated: 12/31/1969
Mercy Hospital
mi
from
Coon Rapids, MN
Click here to add this to my saved trials
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated:  12/31/1969
Fairview Southdale Hospital
mi
from
Edina, MN
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated: 12/31/1969
Fairview Southdale Hospital
mi
from
Edina, MN
Click here to add this to my saved trials
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated:  12/31/1969
Unity Hospital
mi
from
Fridley, MN
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated: 12/31/1969
Unity Hospital
mi
from
Fridley, MN
Click here to add this to my saved trials
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated:  12/31/1969
Fairview Maple Grove Medical Center
mi
from
Maple Grove, MN
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated: 12/31/1969
Fairview Maple Grove Medical Center
mi
from
Maple Grove, MN
Click here to add this to my saved trials
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated:  12/31/1969
Minnesota Oncology Hematology PA-Maplewood
mi
from
Maplewood, MN
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated: 12/31/1969
Minnesota Oncology Hematology PA-Maplewood
mi
from
Maplewood, MN
Click here to add this to my saved trials
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated:  12/31/1969
Saint John's Hospital - Healtheast
mi
from
Maplewood, MN
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated: 12/31/1969
Saint John's Hospital - Healtheast
mi
from
Maplewood, MN
Click here to add this to my saved trials
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated:  12/31/1969
Abbott Northwestern Hospital
mi
from
Minneapolis, MN
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated: 12/31/1969
Abbott Northwestern Hospital
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated:  12/31/1969
Hennepin County Medical Center
mi
from
Minneapolis, MN
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated: 12/31/1969
Hennepin County Medical Center
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated:  12/31/1969
Health Partners Inc
mi
from
Minneapolis, MN
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated: 12/31/1969
Health Partners Inc
mi
from
Minneapolis, MN
Click here to add this to my saved trials
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated:  12/31/1969
New Ulm Medical Center
mi
from
New Ulm, MN
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated: 12/31/1969
New Ulm Medical Center
mi
from
New Ulm, MN
Click here to add this to my saved trials
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated:  12/31/1969
North Memorial Medical Health Center
mi
from
Robbinsdale, MN
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated: 12/31/1969
North Memorial Medical Health Center
mi
from
Robbinsdale, MN
Click here to add this to my saved trials
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated:  12/31/1969
Park Nicollet Clinic - Saint Louis Park
mi
from
Saint Louis Park, MN
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated: 12/31/1969
Park Nicollet Clinic - Saint Louis Park
mi
from
Saint Louis Park, MN
Click here to add this to my saved trials
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated:  12/31/1969
Regions Hospital
mi
from
Saint Paul, MN
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated: 12/31/1969
Regions Hospital
mi
from
Saint Paul, MN
Click here to add this to my saved trials
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated:  12/31/1969
United Hospital
mi
from
Saint Paul, MN
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated: 12/31/1969
United Hospital
mi
from
Saint Paul, MN
Click here to add this to my saved trials
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated:  12/31/1969
Saint Francis Regional Medical Center
mi
from
Shakopee, MN
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated: 12/31/1969
Saint Francis Regional Medical Center
mi
from
Shakopee, MN
Click here to add this to my saved trials
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated:  12/31/1969
Lakeview Hospital
mi
from
Stillwater, MN
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated: 12/31/1969
Lakeview Hospital
mi
from
Stillwater, MN
Click here to add this to my saved trials
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated:  12/31/1969
Ridgeview Medical Center
mi
from
Waconia, MN
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated: 12/31/1969
Ridgeview Medical Center
mi
from
Waconia, MN
Click here to add this to my saved trials
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated:  12/31/1969
Rice Memorial Hospital
mi
from
Willmar, MN
Vismodegib and FAK Inhibitor GSK2256098 in Treating Patients With Progressive Meningiomas
Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas With SMO/AKT/NF2 Mutations
Status: Enrolling
Updated: 12/31/1969
Rice Memorial Hospital
mi
from
Willmar, MN
Click here to add this to my saved trials